141 related articles for article (PubMed ID: 25980534)
1. Actively targeted delivery of doxorubicin to bone metastases by a pH-sensitive conjugation.
Ye WL; Zhao YP; Na R; Li F; Mei QB; Zhao MG; Zhou SY
J Pharm Sci; 2015 Jul; 104(7):2293-303. PubMed ID: 25980534
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer.
Ye WL; Zhao YP; Li HQ; Na R; Li F; Mei QB; Zhao MG; Zhou SY
Sci Rep; 2015 Sep; 5():14614. PubMed ID: 26419507
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of doxorubicin α-linolenic acid conjugate and evaluation of its antitumor activity.
Liang CH; Ye WL; Zhu CL; Na R; Cheng Y; Cui H; Liu DZ; Yang ZF; Zhou SY
Mol Pharm; 2014 May; 11(5):1378-90. PubMed ID: 24720787
[TBL] [Abstract][Full Text] [Related]
4. Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity.
Song YF; Liu DZ; Cheng Y; Liu M; Ye WL; Zhang BL; Liu XY; Zhou SY
Sci Rep; 2015 Nov; 5():16125. PubMed ID: 26530454
[TBL] [Abstract][Full Text] [Related]
5. Redox and pH dual sensitive bone targeting nanoparticles to treat breast cancer bone metastases and inhibit bone resorption.
Zhao YP; Ye WL; Liu DZ; Cui H; Cheng Y; Liu M; Zhang BL; Mei QB; Zhou SY
Nanoscale; 2017 May; 9(19):6264-6277. PubMed ID: 28470315
[TBL] [Abstract][Full Text] [Related]
6. Mitochondria and Nucleus Dual Delivery System To Overcome DOX Resistance.
Cui H; Huan ML; Ye WL; Liu DZ; Teng ZH; Mei QB; Zhou SY
Mol Pharm; 2017 Mar; 14(3):746-756. PubMed ID: 28146635
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin.
Xiong XB; Ma Z; Lai R; Lavasanifar A
Biomaterials; 2010 Feb; 31(4):757-68. PubMed ID: 19818492
[TBL] [Abstract][Full Text] [Related]
8. Bone targeting nano-aggregates prepared from self-assembled polyaspartamide graft copolymers for pH sensitive DOX delivery.
Lim CW; Kim D
Biomater Sci; 2021 Mar; 9(5):1660-1667. PubMed ID: 33409517
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Anti-Tumor Effect of Folate-Targeted FA-AMA-hyd-DOX Conjugate in a Xenograft Model of Human Breast Cancer.
Liao TT; Han JF; Zhang FY; Na R; Ye WL
Molecules; 2021 Nov; 26(23):. PubMed ID: 34885691
[TBL] [Abstract][Full Text] [Related]
10. Engineering of Bone- and CD44-Dual-Targeting Redox-Sensitive Liposomes for the Treatment of Orthotopic Osteosarcoma.
Feng S; Wu ZX; Zhao Z; Liu J; Sun K; Guo C; Wang H; Wu Z
ACS Appl Mater Interfaces; 2019 Feb; 11(7):7357-7368. PubMed ID: 30682240
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer.
Colombo PE; Boustta M; Poujol S; Jarlier M; Bressolle F; Teulon I; Ladjemi MZ; Pinguet F; Rouanet P; Vert M
Gynecol Oncol; 2011 Sep; 122(3):632-40. PubMed ID: 21665252
[TBL] [Abstract][Full Text] [Related]
12. Poly(2-ethyl-2-oxazoline)-doxorubicin conjugate-based dual endosomal pH-sensitive micelles with enhanced antitumor efficacy.
Li J; Zhou Y; Li C; Wang D; Gao Y; Zhang C; Zhao L; Li Y; Liu Y; Li X
Bioconjug Chem; 2015 Jan; 26(1):110-9. PubMed ID: 25506713
[TBL] [Abstract][Full Text] [Related]
13. Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles.
Ye WL; Du JB; Zhang BL; Na R; Song YF; Mei QB; Zhao MG; Zhou SY
PLoS One; 2014; 9(5):e97358. PubMed ID: 24828815
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of Cancer Chemotherapeutic Efficacy via Bone-Targeted Drug Delivery Carrier in Bone Metastases.
Xue X; Yu J; Lu F; Jiang H; Wang X
Drug Des Devel Ther; 2021; 15():4455-4468. PubMed ID: 34737552
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antitumor activity of a novel pH-activated polymeric drug delivery system for doxorubicin.
Huan M; Zhang B; Teng Z; Cui H; Wang J; Liu X; Xia H; Zhou S; Mei Q
PLoS One; 2012; 7(9):e44116. PubMed ID: 23028490
[TBL] [Abstract][Full Text] [Related]
16. An Acid-Sensitive Nanofiber Conjugate Based on a Short Aromatic Peptide for Targeted Delivery of Doxorubicin in Liver Cancer.
Liang J; Guo R; Xuan M; Sun Q; Wu W
Int J Nanomedicine; 2022; 17():2961-2973. PubMed ID: 35818401
[TBL] [Abstract][Full Text] [Related]
17. Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis.
Ferreira Ddos S; Faria SD; Lopes SC; Teixeira CS; Malachias A; Magalhães-Paniago R; de Souza Filho JD; Oliveira BL; Guimarães AR; Caravan P; Ferreira LA; Alves RJ; Oliveira MC
Int J Nanomedicine; 2016; 11():3737-51. PubMed ID: 27563241
[TBL] [Abstract][Full Text] [Related]
18. Bone metastasis target redox-responsive micell for the treatment of lung cancer bone metastasis and anti-bone resorption.
Ye WL; Zhao YP; Cheng Y; Liu DZ; Cui H; Liu M; Zhang BL; Mei QB; Zhou SY
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):380-391. PubMed ID: 29336169
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific delivery of doxorubicin through conjugation of pH-responsive peptide for overcoming drug resistance in cancer.
Feng C; Rui M; Shen H; Xin Y; Zhang J; Li J; Yue L; Lai W; Xu X
Int J Pharm; 2017 Aug; 528(1-2):322-333. PubMed ID: 28606508
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of an Epidermal Growth Factor Receptor-Targeted Doxorubicin-Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice.
Yang F; Ai W; Jiang F; Liu X; Huang Z; Ai S
J Pharm Sci; 2016 Feb; 105(2):639-649. PubMed ID: 26869425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
